Aim: This study aims to describe the immune infiltrations in low-grade glioma (LGG) with respect to their histological classification, isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation status and survival. Materials and Methods: The IDH1/2 status (mutant or wild-type) of 66 World Health Organization Grade II and III gliomas were defined using next-generation sequencing or multiplex ligation-dependent probe amplification. The immune infiltrates of these tumors (46 mutant IDH, 20 wild-type IDH) were assessed immunohistochemically using a panel of antibodies (CD3, CD4, CD8, FOXP3, CD20, CD68, and CD163). Confirmatory analyses were performed on a cohort of lower grade gliomas from the Cancer Genome Atlas (TCGA). Statistical analyses were perfo...
Abstract The design and evaluation of immunotherapies in IDH-mutant lower grade gliomas (LGG) is hin...
<p>Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive di...
Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical activity in a...
Aim: This study aims to describe the immune infiltrations in low-grade glioma (LGG) with respect to ...
Aim: This study aims to describe the immune infiltrations in low-grade glioma (LGG) with respect to ...
Low-grade gliomas (LGGs), which harbor an isocitrate dehydrogenase (IDH) mutation, have a better pro...
Although the successful clinical trials of immunotherapy show promising strategies for many cancers,...
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates ...
BACKGROUND: Tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) are targets...
Background: Tumor microenvironment, especially infiltrating immune cell, is crucial for solid tumors...
Abstract Background Low grade glioma (LGG) is considered a heterogeneous tumor with highly variable ...
Raushan Auezova,1 Natalia Ivanova,2 Serik Akshulakov,1 Berik Zhetpisbaev,1 Aizhan Kozhakhmetova,1 Nu...
Background: Chromosome 1p/19q codeletion is one of the most important genetic alterations for low gr...
Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical activity in a...
<p>Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive di...
Abstract The design and evaluation of immunotherapies in IDH-mutant lower grade gliomas (LGG) is hin...
<p>Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive di...
Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical activity in a...
Aim: This study aims to describe the immune infiltrations in low-grade glioma (LGG) with respect to ...
Aim: This study aims to describe the immune infiltrations in low-grade glioma (LGG) with respect to ...
Low-grade gliomas (LGGs), which harbor an isocitrate dehydrogenase (IDH) mutation, have a better pro...
Although the successful clinical trials of immunotherapy show promising strategies for many cancers,...
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates ...
BACKGROUND: Tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) are targets...
Background: Tumor microenvironment, especially infiltrating immune cell, is crucial for solid tumors...
Abstract Background Low grade glioma (LGG) is considered a heterogeneous tumor with highly variable ...
Raushan Auezova,1 Natalia Ivanova,2 Serik Akshulakov,1 Berik Zhetpisbaev,1 Aizhan Kozhakhmetova,1 Nu...
Background: Chromosome 1p/19q codeletion is one of the most important genetic alterations for low gr...
Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical activity in a...
<p>Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive di...
Abstract The design and evaluation of immunotherapies in IDH-mutant lower grade gliomas (LGG) is hin...
<p>Background: Malignant gliomas are heterogeneous brain tumors with the potential for aggressive di...
Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical activity in a...